Clinical Trial Update: Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on tolebrutinib, a brain-penetrant Bruton's tyrosine kinase inhibitor, for modulation of chronically inflamed white matter lesions…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tolebrutinib (tolebrutinib)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-13